Curriculum vitae matthew ryan weir, M. D



Download 0.51 Mb.
Page3/7
Date conversion04.02.2017
Size0.51 Mb.
1   2   3   4   5   6   7
. Am J Kidney Dis 2000; 35(3):562.

  • Chrysant SG, Weder AB, McCarron DA, Canossa-Terris M, Cohen JD Gunter PA, Hamilton BP, Lewin AJ, Mennella RF, Kirkegaard LW, Weir MR, Weinberger MH. Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. Am J Hypertens 2000; 13:1180-1188.

  • Weir MR. Preventing renal disease progression: is it the drug or the blood pressure reduction, or both? Curr Hypertens Rep 2000; 2:497-499.

  • Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 2000; 9:403-411

  • Weir MR. When initial antihypertensive monotherapy fails: potential benefits of fixed-dose angiotensin-converting enzyme inhibitor/calcium antagonist combination therapy. Southern Medical Journal 2000; 93:548-556.

  • Klassen DK, Drachenberg, CB, Papadimitriou JC, Cangro CB, Fink JC, Bartlett ST, Weir MR. CMV allograft pancreatitis: diagnosis, treatment, and histological features. Transplantation 2000; (9):1968-1971.

  • Neutel JM, Weir MR, Moser M, Harris S, Edwards D, Michelson EL, Wang R. The effects of candesartan cilexetil in isolated systolic hypertension: A clinical experience trial. J Clin Hypertens 2000; 2:181-186.

  • Weir MR. The role of multiple drug therapies for controlling hypertension in African Americans. J Clin Hypertens 2000; 123:99-108.

  • Bakris GL, Whelton P, Weir MR, et al for the Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Group. Clinical trials in chronic renal disease; what does the future hold? J Clin Pharmacol 2000;40:815-823.

  • Bakris GL, Williams M, Dworkin L Weir MR, et al for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kid Dis 2000; 36:646-661.

  • Dailey GE, Boden GH, Creech RH, Johnson DG, Gleason RE, Kennedy FP, Weinrauch LA, Weir MR, D’Elia JA. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism 2000; 49:1491-1495.

  • Weir MR, Blantz RC. Implications from the Heart Outcomes Evaluation Study. Curr Opin Nephrol and Hypertens 2001; 10:61-63.

  • Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST, Fink JC. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 591567-1571.

  • Weir MR. Diabetes and Hypertension: How Low Should You Go and With Which Drugs? Am J Hypertens 2001; 14:17S-26S.

  • Weir MR, Wei C. The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy. JRAAS 2001; 2(suppl1): S188-S190.

  • Weir MR, Wang RY. Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial. JRAAS 2001; 2(suppl1):S217-S222.

  • Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and angiotensin convertin enzyme inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001; 14:963-968.

  • Weir MR, Weber MA, Neutel JM, Vendetti J, Michelson EL, Wang RY for the ACTION Study Investigators. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. Am J Hypertens 2001; 14:567-572.

  • Weir MR, Smith DHG, Neutel JM, Bedigian MP. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens 2001:14:665-671.

  • Weber MA, Weir MR. Management of high-risk hypertensive patients with diabetes: potential role of angiotensin II receptor antagonists. J Clin Hypertens 2001; 3:225-235.

  • Hanes DS, Weir MR. The beta blockers: are they as protective in hypertension as in other cardiovascular conditions. J Clin Hypertens 2001; 3:236-243.

  • Nogueira JH, Fink JC, Weir MR. Recipient outcome after receiving a laparoscopically harvested kidney from a living donor. Transplantation 2001; 72:355-356.

  • Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazques MA, Weir MR.for the American Society of Transplantation. The evaluation of renal transplant candidates: clinical practice guidelines. Am J Transplant 2001; (suppl 2):1-95

  • Hadley GA, Charandee C, Weir MR, Wang D, Bartlett ST, Drachenburg, CB. Cd103+ accumulate within the graft epithelium during clinical renal allograft rejection. Transplantation 2001:72:1548-155.

  • Fink JC, Salmanullah M, Blahut SA, Weir MR, Sawyer R, Henrich WL, Mise MK. The inevitability of renal function loss in patients with hypercreatinemia. Am J Nephrology 2001:21:386-389.

  • Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104:2280-2288.

  • Drachenberg VC, Drachenberg CB, Papadimitriou MC, Ramos E, Fink JC, Wali R, Weir MR, Cangro CB, Klassen DK, Khaled A, Cunningham R,Bartlett S. Morphological spectrum of polyoma virus disease in renal allografts: Diagnostic Accuracy of urine cytology. American Journal of Transplantation 2001: 1; 373-381.

  • Wiland AM, Fink JC, Philosophe B, Farney AC, Schweitzer EJ, Colonna JO, Weir MR, Bartlett ST. Peripheral administration of thymoglobulin for induction therapy in pancreas transplantation. Transplant Proc 2001;33:1910.

  • Weir MR. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation. Transplant Proc 2001;33 (Suppl 4A):19S-28S.

  • Weir MR. Impact of immunosuppressive regimes on posttransplant diabetes mellitus. Transplant Proc 2001;33(Suppl 5A):23S-26S.

  • Weir MR. Appropriate use of calcium antagonists in hypertension. Hosp Practice 2001:36(9):47-48,53-5.

  • Weir MR. Hypertension in patients with type II diabetes. Hosp Practice 2001;36(1):41-42,47-48,51-54.

  • Weir MR. Commentary: Renal effects of cyclooxygenase-2-selective inhibitors. J Pain and Symptom Management 2002;23:S21.S23.

  • Cunningham RM, Weir MR. Pros and cons of diuretic therapy for hypertension. Emergency Med 2002:34:14-20.

  • Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR: Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol. 2002; 13:2145-2151.

  • Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR: The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2002; 1 Suppl 2:1-95.

  • Weir MR: Renal effects of nonselective NSAIDs and coxibs. Cleve.Clin J Med 2002; 69 Suppl 1:SI53-SI58.

  • Konstam MA, Weir MR: Current perspective on the cardiovascular effects of coxibs. Cleve.Clin J Med 2002; 69 Suppl 1:SI47-SI52.

  • Messerli FH, Weir MR, Neutel JM: Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002; 15:550-556.

  • Haririan A, Ramos ER, Drachenberg CB, Weir MR, Klassen DK: Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. Transplantation 2002; 73:1350-1353.

  • Fink JC, Onuigbo MA, Blahut SA, Christenson RH, Mann D, Bartlett ST, Weir MR: Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case- control study. Am J Kidney Dis. 2002; 39:1096-1101.

  • Fink JC, Blahut SA, Weir MR: Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic renal disease. Am J Kidney Dis. 2002; 39:753-761.

  • Klassen DK, Weir MR, Cangro CB, Bartlett ST, Papadimitriou JC, Drachenberg CB: Pancreas allograft biopsy: safety of percutaneous biopsy-results of a large experience. Transplantation 2002; 73:553-555.

  • Danovitch GM, Hariharan S, Pirsch JD, Rush D, Roth D, Ramos E, Starling RC, Cangro C, Weir MR: Management of the waiting list for cadaveric kidney transplants: report of a survey and recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation. J Am Soc Nephrol. 2002; 13:528-535.

  • Weir MR. Progressive renal and cardiovascular disease: Optimal treatment strategies. Kidney Int 2002; 62:1482-1492.

  • Bakris GL, Weir MR. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: What’s the evidence? J Clin Hypertens 2002; 4:420-423,440.

  • Weir MR. Microalbuminuria as a cardiovascular and renal risk factor in patients with type II diabetes. Am J Clin Proc 2002; 3:7-14.

  • Weir MR: Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. Curr.Hypertens.Rep.2002; 4:333-335.

  • Papadimitriou JC, Drachenberg CB, Klassen DK, Gaber L, Racusen LC, Voska L, Cangro CB, Ramos E, Wali R, Weir MR, Bartlett ST: Histological Grading of Chronic Pancreas Alograft Rejection/Graft Sclerosis. Am J of Transplantation 2003; 3:599-605.

  • Onuigbo M, Weir MR. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes, Obesity and Metabolism 2003; 5:13-26.

  • Weir MR, Sperling RS, Reicin A, Gertz BJ: Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am.Heart J. 146:591-604, 2003

  • Weir MR. Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients? Transplantation Reviews 2003; 17:20-30.

  • Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacology & Therapeutics 2003; 5:427-434.

  • Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM: Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch.Intern.Med. 2003; 163:1555-1565.

  • Weir MR: Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J.Clin.Hypertens.(Greenwich.) 2003; 5:330-335.

  • Mange KC, Weir MR: Preemptive renal transplantation: why not? Am.J.Transplant 2003;3:1336-1340.

  • Lakkis J, Lu WX, Weir MR: RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr.Hypertens.Rep. 2003; 5:408-417.

  • Weir MR: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or CCB vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Curr.Hypertens.Rep. 2003;5:405-407.

  • Weir MR: Clinical trials report. Chronic kidney disease: blood pressure, treatment goals, and cardiovascular outcomes. Curr.Hypertens.Rep.2003;5:405-407.

  • Bakris GL, Weir MR: Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J.Clin.Hypertens. V (III) (Greenwich.) 2003;5:202-209.

  • Lu WX, Lakkis J, Weir MR: Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Curr.Hypertens.Rep.2003;5:192-198.

  • Haririan A, Hamze O, Drachenberg CB, Ramos E, Weir MR, Klassen DK: Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. Transplantation 2003;75:1186-1190.

  • DeMaria AN, Weir MR: Coxibs--beyond the GI tract: renal and cardiovascular issues. J.Pain Symptom.Manage. 2003;25:S41-S49.

  • Weir MR, Blantz RC: Blood pressure and cardiovascular risks: implications of the presence or absence of a nocturnal dip in blood pressure. Curr.Opin.Nephrol.Hypertens. 2003;12:57-60.

  • Weir MR. Commentary on CADI scoring for determining late graft survival: review and case study. The Am J of Urology Review 2004; 2(12) 614-615.

  • Lakkis J, Weir MR: Pharmacological strategies for kidney function preservation: Are there differences by ethnicity? Adv.Ren Replace.Ther. 2004;11:24-40.

  • Ramos E, Vincenti F, Lu WX, Shapiro R, Trofe J, Stratta RJ, Jonsson J, Randhawa PS, Drachenberg CB, Wali RK, Papadimitriou JC, Weir MR, Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004;77:131-133.

  • Wiland AM, Fink JC, Weir MR, Philosophe B, Blahut S, Weir MR, Jr., Copenhaver B, Bartlett ST: Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. Transplantation 2004;77:422-425.

  • Weir MR. Microalbuminuria in Type 2 Diabetics: An Important, Overlooked Cardiovascular Risk Factor. J Clin Hypertens 2004; 6:134-141.

  • Hanes DS, Nahar A, Weir MR: The Tissue Renin-Angiotensin-Aldosterone System in Diabetes Mellitus. Curr. Hypertens.Rep. 2004; 6:98-105.

  • Weir MR: Blood Pressure Management in the Kidney Transplant Recipient. Adv.Chronic Kidney Dis. 2004; 11:172-183.

  • Bakris GL, Weir MR, Secic M, Brett C, Weis-McNulty A. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004;65:1991-2002.

  • Weir MR. Antiotensin II Receptor Blockers: The Importance of Dose in Cardiovascular and Renal Risk Reduction. J Clin Hypertens 2004; 6:315-323.

  • Weir MR, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK, Cangro CB, Bartlett ST, Fink JC. Late Calcineurin Inhibitor Withdrawal as a Strategy to Prevent Graft Loss in Patients with Suboptimal Kidney Transplant Function. Am J Nephrol 2004;24:379-386.

  • Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V, Brisco MA, Bartlett ST, Weir MR, Ramos E. BK Virus-Associated Nephropathy in Renal Allograft Recipients: Rescue Therapy by Sirolimus-Based Immunosuppression. Transplantation 2004; 78:1069-1073.

  • Weir MR: Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asia-Pacific Rim. Kidney Int; 2004; 66:S38-S39.

  • Weir MR: Clinical trials report. Drug-induced Diabetes: Cardiovascular Implications. Curr. Hypertens. Rep. 2004; 6:365-366.

  • Blantz RC, Weir MR: Are the oxygen costs of kidney function highly regulated? Curr.Opin.Nephrol.Hypertens. 2004; 13:67-71.

  • Drachenberg CB, Papadimitriou JC, Wali R, Nogueira J, Mendley S, Hirsch HH, Cangro CB, Klassen DK, Weir MR, Bartlett ST, Ramos E: Improved outcome of polyoma virus allograft nephropathy with early biopsy. Transplant.Proc. 2004; 36:758-759.

  • Weir MR: Healthy diet and blood pressure. J.Clin.Hypertens.(Greenwich.) 2004; 6:381-382.

  • Weir MR: Dietary salt, blood pressure, and microalbuminuria. J.Clin.Hypertens.(Greenwich.) 2004; 6:23-26.

  • Weir MR: Editorial Commentary. Reduction in Microalbuminuria: A Biomeasure of Therapeutic Success?

    Hypertension. 2005; 45:181-182.

    1. Moser M, Weir MR: Commentary. Treatment of Diabetic Hypertensive Patients: Results of a National

    Survey. J. Clin. Hypertens. 2005; 7:110-111.

    1. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD: Selective Cyclooxygenase-2 Inhibition and

    Cardiovascular Effects: An Observed Study of a Medicaid Population. Arch. Intern. Med. 2005; 2:165, 181- 188.

    1. Weir MR, Fink JC. Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary. Am J Kidney Disease 2005; 45(1): 176-188.

    2. Weir MR: The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. Am.J.Hypertens. 2005; 18:4 Pt 2:100S-105S.

    3. Mimran A, Weir MR: Angiotensin-receptor blockers and diuretics--advantages of combination. Blood Press. 2005; 14:6-11.

    4. Danovitch, GM., Cohen, DJ, Weir MR, Stock, PG, Bennett,WM, Christensen, LL, Sung, RS: Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am.J.Transplant. 2005; 5:4 Pt 2, 904-915.

    5. Weir MR, Blantz RC: The clinical utilization of albuminuria as a surrogate measure of cardiovascular disease burden and risk for events: are we there yet? Curr.Opin.Nephrol.Hypertens. 2005; 14:39-41.

    6. Weir MR, Ferdinand KC, Flack JM, Jamerson KA, Daley W, Zelenofske, AADVANCE investigators: A Noninferiority Comparison of Valsartan/Hydrochlorothiazide Combinations Versus Amlodipine in Black Hypertensives. Hypertension. 2005; 46:508-513.

    7. Wali,R.K.; Wang,G.S.; Gottlieb,S.S.; Bellumkonda,L.; Hansalia,R.; Ramos,E.; Drachenberg,C.; Papadimitriou,J.; Brisco,M.A.; Blahut,S.; Fink,J.C.; Fisher,M.L.; Bartlett,S.T.; Weir,M.R.: Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J.Am.Coll.Cardiol. 2005; 45:7, 1051-1060.

    8. Mishra SI, Jones-Burton C, Fink JC, Brown JB, Bakris GL, Weir MR: Does Dietary Salt Increase the Risk for Progression on Kidney Disease? Curr Hypertension Reports. 2005; 7:385-391.

    9. Weir MR. Blood pressure salt sensitivity: a biomeasure of kidney disease susceptibility in diabetics? Nephrology Dialysis Transplant 2005 20(10):2022-2024.

    10. Gotto Jr AM, Blackburn GL, Dailey III GE, Garber AJ, Grundy SM, Sobel BE, Weir MR: The metabolic syndrome: a call to action. Coronary Artery Disease 2006, (1) 17:77-80.

    11. Jones JM, Park JJ, Johnson J, Vizciano D, Brian H, Ferrell R, Weir M, Dowling T, Bobisean T, Brown M: Renin-angiotensin system genes and exercises training-induced changes in sodium excretion in African American hypertensives. Ethnicity & Disease 2006, 16: 666-674.

    12. Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL, Weir MR. An In-Depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease. Am J Nephrol 2006;26:268-75.

    13. Weir MR. Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. J Clin Hypertens (Greenwich ) 2006 February;8(2):99-105.

    14. Shaya FT, El Khoury AC, Mullins CD, Du D, Skolasky R, Fatodu H, Garber H, Weir MR. Drug therapy persistence and stroke recurrence. Am J Manag Care 2006 June;12(6):313-9.

    15. Weir MR. Treatment of prehypertension: how soon is soon enough? What therapy should be used? Curr Hypertens Rep 2006 October;8(5):393-4

    16. Russell M, Fleg JL, Galloway WJ, Henderson JA, Howard J, Lee ET, Poolaw B, Ratner RE, Roman MJ, Silverman A, Weir MR et al. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes--the Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J 2006 November;152(5):867-75.

    17. Weir MR. How Do You Define “Hypertension” in a Patient with Type 1 Diabetes? Hypertension 2007 January 49(1) 13-14.

    18. Weir MR. Is it the low-protein diet or simply the salt restriction? Kidney Int 2007 February;71(3):188-90.

    19. Weir MR. Crikelair N, Levy D, Rocha R, Kuturu V, Glazer R. Evaluation of the Dose Response With Valsartan and Valsartan/Hydrochlorothiazide in Patients With Essential Hypertension. J Clin Hypertens (Greenwich ) 2007 February;9(2):103-12.

    20. Bakris GL, Weir MR, Black HR. Improving blood pressure control rates: is there more we can do? J Clin Hypertens (Greenwich ) 2007 February;9(2):134-42.

    21. Goel R, Majeed F, Vogel R, Corretti MC, Weir M, Mangano C, White C, Plotnick GD, Miller M: Exercise-induced hypertension, endothelial dysfunction, and coronary artery disease in a marathon runner. Am J Cardiol 2007;99:743-744.

    22. Hanes DS, Weir MR. Usefulness of ARBs and ACE Inhibitors in the Prevention of Vascular Dementia in the Elderly. Am J Geriatr Cardiol 2007;16(3):175-82.

    23. Wali RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, Dinits M, Joshi A, Philosophe B, Foster C, Cangro C, Nogueira J, Cooper M, Bartlett ST, Weir MR. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007 (6):1572-83.

    24. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de ZD. Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial. J Am Soc Nephrol 2007;(5):1540-6.

    25. Jones-Burton C., Seliger SL, Scherer RW, Mishra, SI, Vessal G, Brown J, Weir MR, Fink JC. Cigarette Smoking and Incident Chronic Kidney Disease: A Systemic Review. Am JNephrol 2007; 27:342-351.

    26. Weir MR. Calcium Channel Blockers: Their Pharmacologic and Therapeutic Role in Hypertension. Am J Cardiovasc Drugs 2007; 7 Suppl. 1: 5-15.

    27. Weir MR: Microalbuminuria and Cardiovascular Disease. Clin J Am Soc Nephrol 2: 581-590, 2007.

    28. Vessal G, Wiland AM, Philosophe B, Fink JC, Weir, MR et al.: Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. Clincal Transplantation 2007:21: 491-497.

    29. Weir MR, Levy D, Crikelair N et al.: Time to Achieve Blood-Pressure Goal: Influence of Dose of Valasartan Monotherapy and Valsartan and Hydrochlorothiazide Combination Therapy. American Journal of Hypertension 20:807-815, 2007.

    30. Weir MR, Bush C, Anderson DR et al.: Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension. Journal of American Society Hypertension 1(4), 264-277. 2007.

    31. Thoenes M, Bramlage Weir MR, et al: Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular diseas. Future Cardiology 2007; 3 (5): 519-524.

    32. Weir MR. Effects of Renin-Angiotensin System Inhibition on End-Organ Protection: Can We Do Better? Clinical Therapeutics 2007; 29 (9): 1803-1824.

    33. Weir MR. Direct Renin Inhibitors: Where Will They Fit in for Antihypertensive Treatment? Current Hypertension Reports 2007, 9(5): 389-391.

    34. Weir MR. Is Anemia a Predictor for Mortality and Loss of Graft in Kidney Transplant Recipients? American Journal of Tranplantation 2007; 7: 731-732.

    35. Weir MR, Neutel JM, Bhaumik A, et al.:The Efficacy and Safety of Initial Use of Irbesartan/Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Patients with and Without High Cardiovascular Risk. J Clin Hypertens 2007; 12(5) 15-22.

    36. Weber MA, Bakris GL, Dahlof B, Pitt B, Velaquez E, Gupte J, Weir MR, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press 2007;16:13-9.

    37. Nogueira J, Weir MR. The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs. Clin J Am Soc Nephrol 2007; 2: 766–785,.

    38. Weir MR. Risk-Based Classification of Hypertension and the Role of Combination Therapy. J Clin Hypertens 2008; 1(1):4-8

    39. Singh P, Deng A, Weir MR, Blantz R: The balance of angiotensin II and nitric oxide in kidney diseases. Curr Opin Nephrol Hypertens 2008; 17:51-56.

    40. Howard BV, Roman M, Devereux RB, Weir MR, et al. Effects of Lower Target for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial. JAMA 2008 Apr 9;299(14):1678-89.

    41. Bakris GL, Weir MR. Comparison of Dual RAAS Blockade and Higher-Dose RAAS Inhibition on Nephropathy Progression. Postgraduate Medicine 2008;120:33-42.

    42. Weir MR, Bakris GL. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? J Clin. Hypertens. (Greenwich.) 2008;10:146-52.

    43. Gradman AH, Weir MR, Bakris GL. Newer Combination Therapies in the Management of Hypertension: An Update. J Clin Hypertens 2008:10:398-405.

    44. Bakris, GL, Weir MR, Davidai G, Koval S. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 2008;74:364-9.

    45. Mitchell BD, McArdle PF, Shen H, Rampersaud E, Pollin TI, Bielak LF, Jaquish C, Douglas JA, Roy-Gagnon MH, Sack P, Naglieri R, Hines S, Horenstein RB, Chang YP, Post W, Ryan KA, Brereton NH, Pakyz RE, Sorkin J, Damcott CM, O’Connell JR, Mangano C, Corretti M, Vogel R, Herzog W, Weir MR, et al. The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. Am Heart J. 2008 May; 155(5):823-8.

    46. Weir MR. Is Activated Vitamin D Supplementation Renoprotective? Hypertension 2008;52:211-212.

    47. Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A. Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients. Am J Transplant 2008;8:1384-1392.

    48. Nogueira J, Jacobs SC, Haririan A, Phelan MW, Weir MR, Seliger SL, Hurley HA, Cooper M. A single center comparison of long-term outcomes of renal allografts procured laparoscopically versus historic controls procured by the open approach. Transplant International 2008; 9:908-914.

    49. Roy-Gagnon MH, Weir MR, Sorkin JD et al. Genetic influences on blood pressure response to the cold pressor test: results from the Heredity and Phenotype Intervention Heart Study. J Hypertens 2008;26: 729-736.

    50. Weir MR. The Advantage of Single-Pill Combination Therapy Based on Recent Clinical Information. The Journal of Medicine 2008;1(1):72-78.

    51. McArdle PF, Parsa A, Chang YP, Weir MR, etc. Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. Arthritis Rheum. 2008 Sep; 58(9):2874-81.

    52. Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon, Powe NR, Fink NE, Sadler JH, Weir MR, etc. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008 Oct;40(10):1185-92.

    53. Akinbamowo AO, Salzberg DJ, Weir MR. Renal consequences of prostaglandin inhibition in heart failure. Heart Failure Clinics. 2008 Oct;4(4):505-10.

    54. Weir MR. Are we “ONTARGET” yet with regard to optimal antihypertensive regimens? Curr Hypertens Rep. 2008 Oct; 10(5):385-6.

    55. Weir MR. Optimizing Early De Novo Immunosuppression With Sirolimus. Transplantation Proceedings, 2008;40:S29-S31.

    56. Weir MR. Clinical Commentary: how to choose blood pressure goals and treatment: influence of estimated glomerular filtration rate and albuminuria. Trans Am Clin Climatol Assoc. 2008; 119:53-61; discussion 61-3.

    57. Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of irbesartan / hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Clin.Ther. 2008 Dec:30 (12) : 2354-65.

    58. Fleg, JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, etc. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Arthrosclerosis in Native Diabetics Study) trial. J AM Coll Cardiol. 2008 Dec 16;52(25):2198-205.

    59. Wali RK, Weir MR. Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant. 2008 Dec; 13(6):614-21.

    60. Bradbury BD, Critchlow CW, Weir MR, Stewart R, et al. Impact of elevated C-reactive protein levels on erythropoiesis-stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrology Dialysis Transplantation 2009 24(3):919-925.

    61. Nogueira JM, Haririan A, Jacobs SC, Weir MR, Hurley A, Al-Qudah HS, Phelan M, Drachenberg CB, Bartlett ST, and Copper M. The Detrimental Effect of Poor Early Graft Function after Laparoscopic Live Donor Nephrectomy on Graft Outcomes. Am J Transplant 2009; 9:337-347.

    62. Weir MR. The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. Postgrad Med. 2009 Jan; 121(1): 96-103.

    63. Onukwugha E, Weir MR. The dual impact of rehabilitation admission and race/ethnicity on discharges against medical advice. NeuroRehabilitation. 2009;24(1): 67-74.

    64. Shaya FT, Du D, Gbarayor CM, French-Tamas F, Lau H, Weir MR. Predictors of compliance will antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc. 2009 Jan;101(1):34-9.

    65. Weir MR. Assessing the blood pressure-lowering efficacy of antihypertensive medications: which blood pressures should we use? J Clin Hypertens (Greenwhich). 2009 Mar;11 (3):155-8.

    66. Weir MR, Wali RK. Minimizing the risk of chronic allograft nephropathy. Transplantation. 2009 April 27;87 (8 Suppl):S14-8.

    67. Krum H, Swergold G, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, et. al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. J Hypertens. 2009 Apr;27(4):886-93.

    68. Weir MR.  Blockers in the Treatment of Hypertension: Are There Clinically Relevant Difference? Postgrad Med. 2009 May; 121(3): 90-98.

    69. Mohamed MA, Weir MR. Renin angiotensin system inhibition in the older person: a review. Clin Geriatr Med. 2009 May;25(2):245-57.

    70. Badowski M, Gurk-Turner C, Cangro C, Weir M, Philosophe B, et. al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant 2009 July: 23: 930-937

    71. Krum H, Curtis SP, Kaur A, Wang H, Smugar SS, Weir MR, et al. Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. Eur J Heart Fail. 2009 June;11 (6):542-50.

    72. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL,Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009 June 22;169(12):1156-62.

    73. Weir MR. Hypertension and the Kidney: Perspectives on the Relationship of Kidney Disease and Cardiovascular Disease. Clin J Am Soc Nephrol 2009 July 16 (4): 2045–2050.

    74. Onukwugha EC, Shaya FT, Saunders E, Weir MR. Ethnic disparities, hospital quality, and discharges against medical advice among patients with cardiovascular disease. Ethn Dis, 2009 Spring;19(2):172-8.

    75. Weir MR, Townsend RR. What is left ventricular hypertrophy and is there a reason to regress left ventricular hypertrophy? J Clin Hypertens. 2009 Aug;11(8):407-10.

    76. Weir MR, Anderson CA. Optimal Dietary Strategies for Reducing Incident Hypertension. Hypertension. 2009 ; 54:698-699

    77. Weir MR. Wali RK. Optimizing immunosuppression with sirolimus in the first year posttransplantation: experience in the United States. Transplant Proc. 2009.Jul-Aug;41(6 Suppl):S13-7.

    78. Manitpistkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens. 2009 Sep;18(5):404-11.

    79. Weir MR, Yeh F, Silverman A, Devereux RB, Galloway JM, Henderson JA, Howard WJ, et. al. Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. J Clin Hypertens (Greenwich). 2009 Oct;11(10):540-8.

    80. Weir MR, and Townsend R. Gauging adequacy of cardiovascular disease treatment: importance of estimating glomerular filtration rate and time-varying albuminuria. J Am Soc Hypertens 2009;3(4):277-285.

    81. Blak BT, Mullins CD, Shaya FT, Simoni-Wastila L, Cooke CE, Weir MR. Prescribing Trends and Drug Budget Impact of the ARBS in the UK. Value in Health 2009; 12(2):302-308.

    82. Nogueira JM, Weir MR, Jacobs S, Breault D, Klassen D, Evans DA, Bartlett ST, Cooper M. A study of Renal Outcomes in Obese Living Kidney Donors. Transplantation. 2009 Dec 27;88(12):1371-6.

    83. Shaya FT, Lu Z, Sohn K, Weir MR. Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents. PT. 2009 Sep;34(9): 490-501.

    84. Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G, Remuzzi G. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. J Hypertens. 2010 Jan;28(1):186-93.

    85. Weir MR, Bogle LL, Mackowiak PA. The Death of John Paul Jones and Resurrection as ‘Father of the US Navy’. Am J Nephrol. 2010;31(1):90-4.

    86. Stevens LA, Schmid CH, Zhang YL, Coresh J, Manzi J, Landis R, Bakoush O, Contreras G, Genuth S, Klintmalm GB, Poggio E, Rossing P, Rule AD, Weir MR, et. al. Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant. 2010 Feb;25(2):449-57.

    87. Weir MR. Relative plasma volume monitoring and blood pressure control: an overlooked opportunity to achieve dry weight in the hemodialysis patient. Hypertension. 2010 Feb;55(2):226-7.

    88. Weir MR, Rolfe M. Potassium hemeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010 Mar;5(3):531-48.

    89. Haririan A, Nogueira JM, Zandi-Nejad K, Aiyer R, Hurley H, Cooper M, Klassen DK, Weir MR. The independent association between serum uric acid and graft outcomes after kidney transplantation. Transplantation. 2010 Mar 15;89(5):573-9.

    90. Townsend RR, Wimmer NJ, Chirinos JA, Parsa A, Weir M, Perumal K, et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens. 2010 Mar;23(3):282-9.

    91. Weir MR. Hypertension: Endothelin-receptor antagonists for treating hypertension. Nat Rev Nephrol. 2010 Apr;6(4):192-4.

    92. Bakris GL, Sarafidis PA, Weir MR, Dahlof B, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet. 2010 Apr 3;375(9721):1173-81.

    93. Wilson C, Huang CC, Shara N. Howard BV, Fleg JL, Henderson JA, Howard WJ, Huentelman H, Lee ET, Mete M, Russell M, Galloway JM, Silverman A, Stylianou M, Umans J, Weir MR, Yeh F, Ratner RE. Cost-effectiveness of lower targets for blood pressure and LDL cholesterol in diabetes: the stop atherosclerosis in native diabetics study (SANDS). J Clin Lipidol. 2010 May;4(3):165-172.

    94. mTOR inhibition: the learning curve in kidney transplantation. Weir MR, Diekmann F, Flechner SM, Lebranchu Y, Mandelbrot DA, et al. Transpl Int. 2010 May 1;23(5):447-60.

    95. Szczech LA, Granger CB, Dasta JF, Amin A, Peacock WF, McCullough PA, Devlin JW, Weir MR, et al. Acute kidney injury and cardiovascular outcomes in acute severe hypertension. Circulation. 2010 May 25;121(20):2183-91.

    96. Nogueira JM, Haririan A, Jacobs SC, Cooper M, Weir MR. Cigarette smoking, kidney function, and mortality after live donor kidney transplant. Am J Kidney Dis. 2010 May;55(5):907-15.

    97. Weir MR, Bakris GL. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010;31(5):469-70.

    98. Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, O’Connor A, Perumal K, Rahman M, Steigerwalt S, Teal V, Townsend R, Weir MR, et al. Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2010 Mar;55(3):441-51.

    99. Joffe, M, Hsu, C, Feldman, HI, Weir M, landis JR, et al. Variability of Creatinine Measurements in Clinical Laboratories: Results from the CRIC Study. Am J Nephrol 2010; 31:426-434. DOI: 10.1159/000296250.

    100. Onukwugha E, Saunders E, Mullins CD, Pradel FG, Zuckerman M, Weir MR. Reasons for discharges against medical advice: a qualitive study. Qual Saf Health Care. 2010;19:420-424.

    101. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, et. al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29;56(1):77-85.

    102. Agarwal R, Weir MR. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. Clin J Am Soc Nephrol. 2010 Jul;5(7):1255-60.

    103. Weir MR, Zappe D, Orloski LA, Sowers JR. How early should blood pressure control be achieved for optimal cardiovascular outcomes? J Hum Hypertens. 2011 Apr;25(4):211-7.

    104. Weir MR, Yadao AM, Purkayastha D, Charney AN. Effects of High-and Low-Sodium Diets on Ambulatory Blood Pressure in Patient With Hypertension Receiving Aliskiren. J Cardiovasc Pharmacol Ther. 2010 Dec;15 (4):356-63.

    105. Townsend RR, Chirinos JA, Parsa A, Weir MR, Sozio SM, Lash JP, et al. Central pulse pressure in chronic kidney disease: a chronic renal insufficiency cohort ancillary study. Hypertension. 2010 Sep;56(3):518-24.

    106. Lattanzio MR, Weir MR. Have we fallen off target with concerns surrounding dual RAAS blockade? Kidney Int. 2010 Sep;78(6):539-45.

    107. Weir MR. Hypervolemia and blood pressure: powerful indicators of increased mortality among hemodialysis patients. Hypertension. 2010 Sep;56(3):341-3.

    108. DeSilva L, Weir MR. Renin inhibition and microalbuminuria development: meaning predictor of kidney disease progression. Curr Opin Nephrol Hypertens. 2010 Sep;19(5):437-43.

    109. Weir MR. Dietary fructose and elevated levels of blood pressure. J Am Soc Nephrol. 2010 Sept;21(9):1416-8.

    110. Weir MR, Bakris GL. Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study. Curr Hypertens Rep. 2010 Oct;12(5):313-5.

    111. Lattanzio MR, Weir MR. Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease? Curr Hypertens Rep. 2010 Oct;12(5):369-77.

    112. Weinrauch LA, Sun J, Gleason RE, Boden GH, Creech RH, Dailey G, Kennedy FP, Weir MR, D’Elia JA. Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. Metabolism. 2010 Oct;59(10):1429-34.

    113. Russell M, Silverman A, Fleg JL, Lee ET, Mete M, Weir M, Wilson C, Yeh F, Howard BV, Howard WM. Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study. J Clin Lipidol. 2010 Sep-Oct;4(5):435-43.

    114. Wali RK, Lyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK. Efficacy and Safety of Carvediolol in Treatment of Heart Failure in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials. Circ Heart Fail. 2011 Jan;4(1):18-26.

    115. Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies. J Hum Hypertens. 2010 Nov;24(11):721-9.

    116. Onukwugha E, Mullins CD, Loh FE, Saunders E, Shaya FT, Weir MR. Readmissions after unauthorized discharges in the cardiovascular setting. Med Care. 2011 Feb; 49(2):215-24.

    117. Weir MR, Punzi HA, Flack JM, Stoakes KA, Chavanu KJ, et al. A Randomized, Double-Blind, Forced-Titration Study to Compare Olmesartan Medoxomil Versus Losartan Potassium in Patients with Stage 1 and 2 Hypertension. Postgraduate Medicine. 2011 Jan; 123(1):80-87.

    118. Jamerson KA, Devereux R, Bakris GL, Dahlof B, Velazquez EJ, Weir M, et al. Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension. 2011 Feb; 57(2):174-9.

    119. Weir MR, Mulgaonkar S, Chan L, Shidban H, et al. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kid Int. 2011; (79) 897-907.

    120. Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis CJ, Fink JC. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. 2011 Aug;80(3):288-94.

    121. Weir MR, Bartlett ST, Drachenberg CB. Eosinophilia as an early indicator of pancreatic allograft rejection. Clin Transplant. 2012 Mar-Apr;26(2):238-41.

    122. Weir MR, Aronson S, Avery EG, Pollack CV Jr. Acute kidney injury following cardiac surgery: role of perioperative blood pressure control. Am J Nephrol. 2011;33(5):438-52.

    123. McMahon G, Weir MR, Li XC, Mandelbrot DA. The Evolving Role of mTOR Inhibition in Transplantation Tolerance. J AM Soc Nephrol 2011 (22): 408-415.

    124. Sharma AM, Weir MR. The role of angiotensin receptor blockers in diabetic nephropathy. Postgrad Med. 2011 May;123(3):109-21.

    125. Schmieder RE, Bakris G, Weir MR. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-June;24(3):263-73.

    126. Krum H, Swergold G, Gammaitoni A, Peloso PM, Smugar SS, Curtis SP, Brater DC, Wang H, Kaur A, Laine L, Weir MR, Cannon CP. Blood Pressure and Cardiovascular Outcomes in Patients Taking Nonsteroidal Antiinflammatory Drugs. Cardiovasc Ther. 2012 Dec;30(6):342-350.

    127. Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M. Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the Folic Acid for Vascular Outcome Reduction in Transplantation Trial. Circulation. 2011;123:1763-1770.

    128. Weir MR, Hsueh WA, Nesbitt SD, Littlejohn TJ 3rd, Graff A, et. al. A Titrate-to-Goal Study of Switching Patients Uncontrolled on Antihypertensive Monotherapy to Fixed-Dose Combinations of Amlodipine and Olmesartan Medoxomil ± Hydrochlorothiazide. J Clin Hypertens (Greenwich). 2011 Jun;13(6):404-12.

    129. Weir MR and Salzberg Daniel J. Management of hypertension in the transplant patient. JASH 2011 5(5):425-432.

    130. Weir MR, Hollenberg NK, Remuzzi G, Zappe DH, Meng X, Parving HH. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. J Hypertens. October 2011, 29(10):2031-2037.

    131. Weir MR. Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success? Kidney Int. 2011 Aug;80(3):235-7.

    132. Weir MR, Townsend RR, Fink JC, Teal V, Anderson C, Appel L, et. al. Hemodynamic Correlates of Proteinuria in Chronic Kidney Disease. Clin J Am Soc Nephrol. October 2011;6:(10):2403-2410.

    133. Weir MR, Izzo JL Jr. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich). 2011 Sep;13(9):667-75.

    134. Haririan A, Metireddy M, Cangro C, Nogueira JM, Rasetto F, Cooper M, Klassen DK, Weir MR. Association of serum uric Acid with graft survival after kidney transplantation: a time-varying analysis. Am J Transplant. 2011 Sept; 11(9):1943-50.

    135. Hsu C, Propert K, Xie, D, Hamm L, He J, Miller E, Akinlolu O, Shlipak M, Townsend R, Weir M, et al. Measured GFR Does Not Outperform Estimated GFR in Predicting CKD-related Complications. J Am Soc Nephrol 2011(22):1931-1937.

    136. Montasser ME, Douglas JA, Roy-Gagnon M, Van Hout CV, Weir MR, et. al. i Response to Low-Salt Intake in a Healthy Adult Population. J Clin Hypertens (Greenwich). 2011;13:795-800.

    137. Weir MR. Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. Kidney Int. 2011 Nov;10(2):1016-1017.

    138. Scialla J, Leonard MB, Townsend R, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, Hanish A, Raj D, Rosas SE, Seliger SL, Weir MR, Parekh RS on behalf of the CRIC Study Group. Correlates of Osteoprotegerin and Association with Aortic Pulse Wave Velocity in Patients with Chronic Kidney Disease. Clin J Am Soc Nephrol. 2011;6:2612-2619.

    139. Weir MR. Optimal Treatment Strategies for Patients with Hypertension and Diabetes Are Effects on Metabolism Important? Hypertension. 2011;58:789-759.

    140. Weir MR. Recognizing the link between chronic kidney disease and cardiovascular disease. Am J Manag Care. 2011 Dec; 17 Suppl 15:S396-402.

    141. Weir MR. Body mass index-mortality paradox in hemodialysis patients: blood pressure, blood volume, and nutritional status. Hypertension. 2011 Dec;58(6):989-90.

    142. Weir MR. Recognizing the link between chronic kidney disease and cardiovascular disease. Am J Manag Care. 2011 Dec; Suppl 15:S396-402.

    143. Greathouse MK and Weir MR. The Role of ARBs Alone or with HCTZ in the Treatment of Hypertension and Prevention of Cardiovascular and Renal Complications. Postgrad Med. 2012 Mar;124(2):40-52.

    144. Jones H, Talwar M, Nogueira JM, Ugarte R, Cangro C, Rasheed H, Klassen DK, Weir MR, Haririan A. Anemia After Kidney Transplantation: Its Prevalence, Risk Factors, and Independent Association with Graft and Patient Survival: A Time-Varying Analysis. Transplantation. 2012 May 15;93(9):923-8.

    145. Weir MR, Bakris GL, Weber MA, Dahlof B, Devereux RB, Kjeldsen SE, Pitt B, Wright JT, Kelly RY, Hua TA, Hester RA, Velazquez E, Jamerson KA. Renal Outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar;81(6):568-76.

    146. Parsa A, Brown E, Weir MR, Fink JC, Shuldiner AR, Mitchell BD, McArdle PF. Genotype-based changes in serum uric acid affect blood pressure. Kidney Int. 2012 Mar;81(5):502-7.

    147. Mohanlol V, Parsa A, Weir MR. Role of dietary therapies in the prevention and treatment of hypertension. Nat Rev Nephrol. 2012 May 15;8(7):413-22.

    148. Weir MR, Agarwal R. Thiazide and thiazide-like diuretics: perspectives on individualization of drug and dose based on therapeutic index. Hypertension. 2012 Jun;59(6):1089-90.

    149. Scialla JJ, Appel LJ, Wolf M, Yang W, Zhang X, Sozio SM, Miller ER 3rd, Bazzano LA, Cuevas M, Glenn MJ, Lustigova E, Kallem RR, Porter AC, Townsend RR, Weir MR, Anderson CA; Chronic Renal Insufficiency Cohort (CRIC) Study Group. J Ren Nutr. 2012 Jul;22 (4):379-388.

    150. Onukwugha E, Saunders E, Mullins CD, Pradel FG, Zuckerman M, Loh FE, Weir MR. A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting. BMJ Open. 2012 Jul 30;2(4).

    151. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA; on behalf of the American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease. Circulation. 2012 Jul 31; 126 (5):617-663.

    152. Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation – evidence from the FAVORIT study. Clin Transplant. 2012 Jul;26(4):E438-46.

    153. Lentine KL, Costa SP, Weir MR, Robb JF, Fleisher LA, Kasiske BL, Carithers RL, Ragosta M, Bolton K, Auerbach AD, Eagle KA; American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease. Cardiac disease evaluation and management among kidney disease and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cariology Foundation. J Am Coll Cardiol. 2012 Jul 31;60(5): 434-80.

    154. Weir MR. Improving the estimating equation for GFR-a clinical perspective. N Engl J Med. 2012 Jul 5;367 (1):75-6.

    155. Weir MR, Drachenberg CB. A 72-year-old woman with several months of weight loss and generalized weakness. Am J Med Sci. 2012 Aug; 344(2):142-5.

    156. Patel K, Diamantidis C, Zhan M, Hsu VD, Walker LD, Gardner J, Weir MR, Fink JC. Influence of Creatinine versus Glomerular Filtration Rate on Non-Steroidal Anti-Inflammatory Drug Prescriptions in Chronic Kidney Disease. Am J Nephrol. 2012; 36(1): 19-26.

    157. Anderson AH, Yang W, Hsu CY, Joffe MM, Leonard MB, Xie D, Chen J, Greene T, Jaar BG, Kao P, Kusek JW, Landis JR, Lash JP, Townsend RR, Weir MR, Felman; CRIC Study Investigators. Estimating GFR Among Participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2012 Aug (2):250-61.

    158. Karadsheh F, Weir MR. Thiazide-like Diuretics: An opportunity to Reduce Blood Pressure in Patients with Advanced Kidney Disease. Curr Hypertens Rep. 2012 Oct;14(5):416-20.

    159. Weir MR, Townsend RR, Fink JC, Teal V, Sozio SM, Anderson CA, Appel LJ, Turban S, Chen J, He J, Litbarg N, Ojo A, Rahman M, Rosen L, Steigerwalt S, Strauss L, Joffee MM. Urinary Sodium Is a Potent Correlate of Proteinuria: Lessons from the Chronic Renal Insuffficiency Cohort Study. Am J Nephrol. 2012 Oct 12; 36(5):397-404.

    160. Weir MR. Debate from the 2012 ASH Annual Scientific Sessions: should blood pressure be reduced in hemodialysis patients? con position. J Am Soc Hypertens. 2012 Nov/Dec; 6(6):443-447

    161. Nesbitt SD, Shojaee A, Maa J-F, and Weir MR. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). J of Human Hypertens. 2013 Jul;27(7):445-52.

    162. Papadimitriou JC, Drachenberg CB, Ramos E, Kukuruga D, Klassen DK, Ugarte R, Nogueira J, Cangro C, Weir MR, Haririan A. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and cause for biopsies. Transplantation. 2013 Jan 15;95(1):128-36.

    163. Mullins CD, Jain R, Weir MR, Franey CS, Shih YC, Pradel FG, Bikov K, Bartlett ST. Benefits improvement and protection act’s impact on transplantation rates among elderly MEDICARE beneficiaries with end-stage renal disease. Transplantation. 2013 Feb 15;95(3):463-9.

    164. Townsend RR, Weir MR. Angiotensin II blockade after kidney transplantation. J Am Soc Nephrol. 2013 Feb;24(2):167-8.

    165. Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet. 2013 Feb 16; 381(9866):537-45.

    166. Weir MR, Shojaee, Maa JF. Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or & lt; 65 years with uncontrolled hypertension on prior monotherapy. Postgrad Med. 2013 Mar; 125(2): 124-34.

    167. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US commentary on the 2012 KDIGO clinical practice guidelines for management of blood pressure in CKD. Am J Kidney Dis. 2013 Aug;62(2):201-13.

    168. Agarwal R, Weir MR. Treated hypertension and the white coat phenomenon: office readings are inadequate measures of efficacy. J Am Soc Hypertens. 2013 May-June;7(3):236-43.

    169. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic Blood Pressure and Cardiovascular Outcomes During Treatment and Hypertension. Am J Med. 2013 Jun;126(6):501-8.

    170. Agarwal R, Weir MR. Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis. J Hypertens. 2013 Aug;31(8):1692-701.

    171. Taler SJ, Agarwal R, Bakris GL, Flynn JT, Nilsson PM, Rahman M, Sanders PW, Textor SC, Weir MR, Townsend RR. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. Am J Kidney Dis. 2013 Aug;31(8):1692-701.

    172. Weber MA, Bakris GL, Hester A, Weir MR, Hua TA, Zappe D, Dahlof B, Velazquez EJ, Pitt B, Jamerson K. Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med. 2013 June;126(6):501-8.

    173. Weber MA, Bakris GL, Weir MR, Jamerson K. Obesity, blood pressure, and cardiovascular outcomes – Author’s reply. Lancet. 2013 Jun 8;381(9882):1982-3.

    174. Nesbitt SD, Shojaee A, Maa JF, Weir MR. Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). J Hum Hypertens. 2013 Jul;27(7):445-52.

    175. Kasiske BL, Anderson-Haag T, Ibrahim HN, Pesavento TE, Weir MR, Nogueira JM, Cosio FG, Kraus ES, Rabb HH, Kalil RS, Posselt AA, Kimmel PL, Steffes MW. A Prospective Controlled Study of Kidney Donors: Baseline and 6-Month Follow-up. Am J Kidney Dis. 2013 Sept;62(3):577-86.

    176. Mindikoglu AL, Weir MR. Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. Am J Nephrol. 2013;38(4):345-54.

    177. Salzberg DJ, Karadsheh FF, Haririan A, Reddivari V, Weir MR. Specific Management of Anemia and Hypertension in Renal Transplant Recipients: Influence of Renin-Angiotensin System Blockade. Am J Nephrol. 2013 Dec 19;39(1):1-7.

    178. Weir MR, Townsend RR. Refractory Hypertension: An Important Clinical Phenotype. Hypertension. 2014. Mar; 63(3):447-8.

    179. Weir MR, Townsend RR. Vascular Stiffness as a Surrogate Measure of Mortality in Patients with Chronic Kidney Disease. J Hypertens. 2014 Apr; 32 (4):744-5.

    180. Mindikoglu AL, Dowling TC, Weir MR, Seliger SL, Christenson RH, Magder LS. Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology. 2014 Apr; 59(4):1532-42.

    181. Weir MR, Fink JC. Safety of Medical Therapy in Patients with Chronic Kidney Disease and End-Stage Renal Disease. Curr Opin Nephrol Hypertens. 2014 May;23(3):306-13.

    182. Carpenter MA, John A, Weir MR, Smith SR, Hunsicker L, Kasiske BL, Kusek JW, Bostom A, Ivanova A, Levey AS, Solomon S, Pesavento T, Weiner DE. J AM Soc Nephrol. 2014 Mar 13. [Epub ahead of print]

    183. Weir MR. Salt, hypertension, and proteinuria in diabetic nephropathy. Lancet Diabetes Endocrinol. 2014 May;2(5):351-2.

    184. Mindikoglu AL, Dowling TC, Wong-You-Cheong JJ, Christenson RH, Magder LS, Hutson WR, Seliger SL, Weir MR. A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. Am J Nephrol. 2014;39(6):543-52.

    185. DeSilva L, Diamantidis CJ, Prakash D, Zuckerman M, Weir MR. Usability of Mobile Technology to Screen for Drug-Drug Interactions in Kidney Transplant Patients. Am J Nephrol. 2014 Jul 19;40(2):97-104.

    186. Carpenter MA, John A, Weir MR, Smith SR, Hunsicker L, Kasiske BL, Kusek JW, Bostom A, Ivanova A, Levey AS, Solomon S, Pesavento T, Weiner DE. BP, cardiovascular disease , and death in the folic acid for vascular outcome reduction in transplantation trial. J Am Soc Nephrol. 2014 Jul;25(7):1554-62.

    187. Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR. Assessment and Management of Hypertension in Patients on Dialysis. J Am Soc Nephrol. 2014 Aug;25(8):1630-46.

    188. Weir MR, Kline I, Xie J, Edwards R, Usiskin K. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (epGFR). Curr Med Res Opin. 2014 Sep;30(9):1759-68.

    189. Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, Meininger G. Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients with Type 2 Diabetes Mellitus. J Clin Hypertens (Greenwhich). 2014 Dec;16(12):875-82.

    190. Lakkis JI, Weir MR. Treatment-Resistant Hypertension in the Transplant Recipient. Semin Nephrol. 2014;34(5):560-570.

    191. Weir MR, Gravens-Muller L, Costa N, Ivanova A, Manitpisitkul W, Bostom AG, Diamantidis CJ; on behalf of the FAVORIT Study Investigators. Safety Events in Kidney Transplant Recipients: Results from the Folic Acid for Vascular Outcome Reduction in Transplant Trial. Transplantation, 2014 Nov 12. [Epub ahead of print].

    192. Weir MR. Hypertension and kidney disease. J AM Soc Hypertens. 2014 Nov;8(11):855-7;quiz 858-9.

    193. Weir MR. In the clinic: hypertension. Ann Intern Med. 2014 Dec 2;161(11):ITC1-15;quiz ITC16.

    194. Karadsheh F, Weir MR. The use of thiazides in chronic kidney disease. Curr Hypertens Rev. 2014;10(2):81-5.

    195. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv, Wittes J, Christ-Schmidt H, Berman L, Pitt B; the OPAL-HK Investigators. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21.

    196. Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, Charleston J, He J, Kallem R, Lash JP, Miller ER 3rd, Rahman M, Steigerwalt S, Weir M, Wright JT Jr, Feldman HI; Chronic Renal Insufficiency Cohort Study Investigators. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. Ann Intern Med. 2015 Feb 17;162(4):258-65.

    197. Liu KD, Yang W, Go AS, Anderson AH, Feldman HI, Fischer MJ, He J, Kallem RR, Kusek JW, Master SR, Miller ER 3rd, Rosas SE, Steigerwalt S, Tao K, Weir MR, Hsu CY; CRIC Study Investigators. Urine Neutrophil Gelatinase-Associated Lipocalin and Risk of Cardiovascular Disease and Death in CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2015 Feb;65(2):267-74.

    198. Hart A, Weir MR, Kasiske BL. Cardiovascular risk assessment in kidney transplantation. Kidney Int. 2015 Mar;87(3):527-534.

    199. Weir MR, Burgess ED, Cooper JE, Fenves AZ, Goldsmith D, McKay D, Mehrotra A, Mitsnefes MM, Sica DA, Taler SJ. Assessment and Management of Hypertension in Transplant Patients. J Am Soc Nephrol. 2015 Feb 4.

    200. Weir MR. Is There an Optimal Strategy for Pretransplant Cardiovascular Screening? Transplantation. 2015 April;99(4):656-7.

    201. Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nat Rev Endocrinol. 2015 Apr;11(4):242-252.

    202. Weir MR, Bakris GL, Pit B. New agents for hyperkalemia. N Engl J Med. 2015 Apr 16; 372(16):1570-1.

    203. Hart A, Weir MR, Kasiske BL. The authors reply. Kidney Int. 2015 Apr;87(4):863-4.

    204. Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, Yue S, Vincenti F. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2015 Jun 14. [Epub ahead of print].

    205. Weir MR, Espaillat R. Clinical perspectives on the rationale for potassium supplementation. Postgrad Med. 2015 Jun; 127(5):539-48.

    206. Mindikoglu AL, Dowling TC, Magder LS, Christenson RH, Weir MR, Seliger SL, Hutson WR, Howell CD. Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines. Clin Gastroenterol Hepatol. 2015 Jun 29. Pii:S1542-3565(15)00845-9.[Epub ahead of print]

    207. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators. Effect of Patiromer on Serum Potassium Level in Patients with Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. Jama 2015 July 14;314(2):151-61.

    208. Kasiske BL, Anderson-Haag T, Israni AK, Kalil RS, Kimmel PL, Kraus ES, Kumar R, Posselt AA, Pesavento TE, Rabb H, Steffes MW, Snyder JJ, Weir MR. A prospective controlled study of living kidney donors: three-year follow-up. Am J Kidney Dis. 2015 Jul;66(1):114-24.

    209. Campbell D, Weir MR. Defining, Treating, and Understanding Chronic Kidney Disease – A Complex Disorder. J Clin Hypertens (Greenwich). 2015 Jul;17(7):514-27.

    210. Rubin MF, Weir MR. Access to Kidney Transplantation: Is There a Potential Conflict of Interest? Am J Nephrol. 2015;41(6):502-3. [Epub 2015 Aug 6]

    211. Weir MR. CCR2 inhibition: a panacea for diabetic kidney disease? Lancet Diabetes Endocrinol. 2015 Sep; 3(9):663-7.

    212. He J, Mills KT, Appel LJ, Yang W, Chen J, Lee BT, Rosas SE, Porter A, Makos G, Weir MR, Hamm LL, Kusek JW; Chronic Renal Insufficiency Cohort Study Investigators. Urinary Sodium and Potassium Excretion and CKD Progression. J AM Soc Nephrol. 2015 Sep 17. [Epub ahead of print]

    213. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015 Oct;17(10):1057-65.

    214. Mindikoglu AL, Dowling TC, Schaub DJ, Hutson WR, Potosky DR, Christenson RH, Barth RN, LaMattina JC, Hanish SI, Weir MR, Raufman JP. Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. Dig Dis Sci. 2015 Nov;60(11):3491-4.

    215. Thomas B, Weir MR. The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient. Curr Cardiol Rep. 2015 Nov;17(11):95.

    216. Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL. Kidney Int. 2015 Dec; 88(88)6:1427-1433.

    217. Weir MR. Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria. Nat Rev Nephrol. 2015 Dec; 11(12):691-2.

    218. Wang Z, Zeng C, Villar VA, Chen SY, Konkalmatt P, Wang X, Asico LD, Jones JE, Yang Y, Sanada H, Felder RA, Eisner GM, Weir MR, Armando I, Jose PA. Human GRK4y142V Variant

    219. Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, Brecklin CS, Drawz P, Flack JM, Miller ER 3rd , Steigerwalt SP, Townsend RR, Weir MR, Wright JT Jr. Rahman M. Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study. Hypertension. 2016 Feb; 67(2):387-96.

    220. Weir MR, Blantz RC. Noteworthy observations in hypertension from 2015. Curr Opin Nephrol Hypertens. 2016 Jan;25(1):1-2.

    221. Pitt B, Weir MR. Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment? Eur J Heart Fail. 2016 Feb;18(2):216.

    222. Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, Deo R, Fischer MJ, He J, Hsu CY, Huan Y, Keane MG, Kusek JW, Makos GK, Miller ER 3rd, Soliman EZ, Steigerwalt SP, Taliercio JJ, Townsend RR, Weir MR, Wright JT Jr, Xie D, Rahman M; and the Chronic Renal Insufficiency Cohort Study Investigators. Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. Clin J Am Soc Nephrol. 2016 Apr 7; 11(4):642-52.

    223. Weir MR. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. Postgrad Med. 2016; 128(3):290-8.

    224. Ahmad SB, Inouye B, Phelan MS, Kramer AC, Sulek J, Weir MR, Barth RN, LaMattina JC, Schweitzer EJ, Leeser DB, Niederhaus SV, Barlett ST, Bromberg JS. Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-Term Follow-Up. Transplantation. 2016 Feb;100(2):407-15.

    225. Weber MA, Bloch M, Bakris GL, Weir MR, Zappe DH, Dahlof B, Velazquez EJ, Pitt B, Basile JN, Jamerson K, Hua TA. Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. J Clin Hypertens (Greenwich). 2016 Apr;18(4):299-307.

    226. Weir MR. Current and future treatment options for managing hyperkalemia. Kidney Int Supp 2016 (6):29-34.

    227. Kasiske BL, Kumar R, Kimmel PL, Pesavento TE, Kalil RS, Kraus ES, Rabb H, Posselt AM, Anderson-Haag TL, Steffes MW, Israni AK, Snyder JJ, Singh RJ, Weir MR. Abnormalities in biomarkers of mineral and bone metabolism in kidney donors.Kidney Int. 2016 Jun 28. pii: S0085-2538(16)30203-4. [Epub ahead of print]

    228. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 Jun 24. pii: S0085-2538(16)30186-7. [Epub ahead of print]

    229. Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. Am J Nephrol. 2016;43(4):229-36.

    230. Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, Ferrannini E, Fonseca VA, Garber AJ, Grunberger G, LeRoith D, Umpierrez GE, Weir MR. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016 Jun;22(6):753-62.

    231. Gilbert RE, Weir MR, Fioretto P, Law G, Desai M, Kline I, Shaw W, Meininger G. Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Can J Diabetes. 2016 Jun;40(3):247-57.

    232. Narayan P, Duan B, Jiang K, Li J, Paka L, Yamin MA, Friedman SL, Weir MR, Goldberg ID. Late intervention with the small molecule BB3 mitigates postischemic kidney injury. Am J Physiol Renal Physiol. 2016 Aug 1;311(2):F352-61.

    233. Palmer BF, Clegg DJ, Taylor SI, Weir MR. Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. J Diabetes Complications. 2016 Aug;30(6):1162-6.

    234. Lentine KL, Villines TC, Axelrod D, Kaviratne S, Weir MR, Costa SP. Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies. Transplantation. 2016 Mar 16. [Epub ahead of print]

    235. Weir MR, Pearson TC, Patel A, Peddi VR, Kalil R, Scandling J, Chan L, Baliga P, Melton L, Mulgaonkar S, Waid T, Schaefer H, Youssef N, Anandagoda L, McCollum D, Lawson S, Gordon R. Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. Transplantation. 2016 Mar 4.

    236. Dias C, Moore KT, Murphy J, Ariyawansa J, Smith W, Mills RM, Weir MR. Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. Am J Nephrol. 2016;44(2):169. Epub 2016 Aug 23.

    237. Ravichandran B, Weir MR. The Tyranny of Generic Immunosuppressants. Am J Nephrol. 2016;44(3):204-5. Epub 2016 Aug 31.

    238. Weir MR. Biomarkers for Predicting Improved Outcomes With Renal Artery Stenting. Hypertension. 2016 Sep 19. [Epub ahead of print].

    239. Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B. Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. Clin J Am Soc Nephrol. 2016 Sep 27.

    240. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney Int. 2016 Sep;90(3):696-704.

    241. Liu X, Foster MC, Tighiouart H, Anderson AH, Beck GJ, Contreras G, Coresh J, Eckfeldt JH, Feldman HI, Greene T, Hamm LL, He J, Horwitz E, Lewis J, Ricardo AC, Shou H, Townsend RR, Weir MR, Inker LA, Levey AS; CRIC (Chronic Renal Insufficiency Cohort) Study Investigators. Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD. Am J Kidney Dis. 2016 Sep 20. pii: S0272-6386(16)30374-2.

    242. Kasiske BL, Kumar R, Kimmel PL, Pesavento TE, Kalil RS, Kraus ES, Rabb H, Posselt AM, Anderson-Haag TL, Steffes MW, Israni AK, Snyder JJ, Singh RJ, Weir MR. Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. Kidney Int. 2016 Oct;90(4):861-8.


  • 1   2   3   4   5   6   7


    The database is protected by copyright ©dentisty.org 2016
    send message

        Main page